A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of Orismilast in Adults with Moderate-to-Severe Plaque-Type Psoriasis

To evaluate the efficacy and safety of a modified-release Orismilast tablets in adults with moderate-to-severe plaque-type psoriasis.

Sponsor(s)
UNION Therapeutics A/S
Principal Investigator(s)
Dr. Jonathan Silverberg MD, PHD, MPH
Contact Phone Number
Request Information